Dotarem® (Gadoteric Acid)  

Dotarem® (Gadoteric Acid)  

The 1st macrocyclic gadolinium-based contrast agent (GBCA) on the market1

Contact us

Dotarem® is an ionic, macrocyclic gadolinium-based contrast agent (GBCA). The first marketing authorization of Dotarem® was approved in 1989 in France.1,2 Since then, Dotarem® has been used in clinical practice, delivering effective MR contrast-enhanced examination.3-6

 

Dotarem Website Video Thumb

Stability and experience

Dotarem® by Guerbet, a flagship brand with over 35 years of real-world experience.1,2

Thanks to its chemical structure, Dotarem® offers high thermodynamic and kinetic stability7,8 to minimize the risk of free gadolinium (Gd3+) released. 9-11

Dotarem Website 140Million Doses Graph

Trusted by radiologists12

More than 170 million doses administered globally13: Dotarem® safety profile has continuously been proven by real-world experience2, 4-6, 14

  • The most administered Macrocyclic GBCA in the world15
  • 35 years of clinical experience1-2

dotarem_mri

Learn more about Dotarem®.

Complete the form below to download the material.

Dotarem_short_brochure

Your personal data will be processed by Guerbet in order to contact you. You are informed that Guerbet may use, reproduce, publish, modify, or transmit the information you provide to us with the aim of processing your request. The legal basis for the processing of your personal data is your consent (voluntary registration on the contact form). Your personal data will be stored until signing out using the sign-off link at the bottom of the email. They may be processed by authorized third parties on behalf of Guerbet solely for the purpose of processing your request. You have the right to revoke your consent at any time by signing out using the sign-off link at the bottom of the emails. You have the right to request access to and rectification or erasure of your personal data, or the restriction of processing, by contacting the controller via email at dataprotection.officer@guerbet.com. You have the right to lodge a complaint with the national authority for data protection if you consider that any of your personal data are processed in breach of the applicable law.

Diagnostic Imaging Interconnected Solutions

Driven by its commitment to advance radiology, Guerbet Diagnostic Imaging has designed a comprehensive and complete portfolio of products and solutions for diagnostic imaging.

Diagnostic Imaging Solutions For Radiology

Sources and references

  1. Val M. Runge et al., The developmental history of the gadolinium chelates as intravenous contrast media for magnetic resonance. Invest Radiol. 2011 Dec;46(12):807-16.
  2. Dotarem® CCDS -V3- February 2018
  3. Braun J., et al. Baseline characteristics, diagnostic efficacy, and periexaminational safety of IV gadoteric acid MRI in 148,489 patients. Acta Radiol. 2020.Jul;61(7):910-920.
  4. Soyer P., et al. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study. J Magn Reson Imaging. 2017.Apr;45(4):988–997.
  5. Chang DH., et al. Safety of gadoterate meglumine in over 1600 children included in the prospective observational SECURE study. Acta Radio. 2019. Nov;60(11):1450–1456.
  6. Maravilla K., et al. Comparison of Gadoterate Meglumine and Gadobutrol in the Diagnosis of Primary Brain Tumors: A Double-Blind Randomized Controlled Intraindividual Crossover Study (the REMIND Study). AJNR Am J Neuroradiol. 2017.Sept;38(9):1681-1688
  7. Port M., et al. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals. 2008.21(4):469–490
  8. Frenzel T., et al. Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C. Invest Radiol. 2008.Dec;43(12):817-288.
  9. J.M. Idée et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol. 2006; 2 0(6): 563-576.
  10. M.A. Kirchin et al. Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging. 2003; 14(5): 426-435
  11. Moshe Rogosnitzky and Stacy Branch. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals. 2016; 29: 365–376.
  12. Data on file, Guerbet internal data (2022, Q1, Global, Elma market research)
  13. Data on file, Guerbet internal data (2024, Q1, Global sales data). ** ** Data based on sales estimation and annual results (1989 -2021)
  14. Eric de Kerviler et al, Adverse Reactions to Gadoterate Meglumine: Review of Over 25 Years of Clinical Use and More Than 50 Million Doses. Invest Radiol. 2016 Sep;51(9):544-51.
  15. Data on file, Guerbet internal data (2023, Q4, Global). Data inclusive of the MRI contrast agent brands that belong to Bracco imaging S.p.A, G.E Healthcare, Guerbet Group, and Bayer Pharma AG, in the following countries: Algeria, Argentina, Australia, Austria, Belgium, Bosnia, Brazil, Bulgaria, Canada, Caribbean, Chile, China, Columbia, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Luxembourg, Malaysia, Malta, Mexico, Morocco, Netherlands, New Zealand, Norway, Pakistan, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sri Lanka, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Arab Emirates, United Kingdom, USA, Venezuela. Data exclude generic brands, except GE (Clariscan™) Bayer (Dotagraf), and local generics in Japan.
  16. Data on file, Guerbet internal data (data is adapted, 2019- 2021). Data inclusive of the MRI contrast agent brands that belong to Bracco imaging S.p.A, G.E Healthcare, Guerbet Group, and Bayer Pharma AG, in the following countries: Algeria, Argentina, Australia, Austria, Belgium, Bosnia, Brazil, Bulgaria, Canada, Caribbean, Chile, China, Columbia, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Luxembourg, Malaysia, Malta, Mexico, Morocco, Netherlands, New Zealand, Norway, Pakistan, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sri Lanka, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Arab Emirates, United Kingdom, USA, Venezuela. Data exclude generic brands, except GE (Clariscan™), Bayer (Dotagraf), and local generics in Japan.

Read product information 

P24002793 – April 2024

Cookie disclaimer

Guerbet uses cookies to improve your experience and to analyze traffic patterns of visitors. By continuing your visit on this website without changing your settings, you consent to the use of  cookies in accordance with our Cookie Policy. Find out more